SecBot SecBot

AIDX

20/20 Biolabs, Inc.
Nasdaq· Services-Testing Laboratories· Inc. DE· CIK 0001139685
$0.2400 −0.01 (−4.00%)
Oct 23 4:00 PM ET · prev $0.2500
Market cap
$3.4M
Nano cap
Median target
🔒 Subscribers only
Since first trade
−99.0%
from $23.85 · Feb 19
30 days
−42.9%
from $0.4200
Range since listing
$0.2400–23.85
at the low
Avg volume 20D
135.2K
Oct 19 spike 398.9K
Short interest
45.2K
≈0.3% of shares · −3.5%
Days to cover
1.0
at average volume
Insider net
$0
no open-market trades · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
12
analyzed by SecBot
SecBot read MIXED 5 reports · 90 days
Balance 0 bearish · 1 bullish · 4 neutral oldest → newest, height = score
Avg score ·High conf. 3/5
Strongest NEUTRAL 20/20 Biolabs, Inc. is holding a Special Meeting on December 9, 2026 to seek stockholder approval for a…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersNO TRADES

    No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.

  • InstitutionsMIXED

    Q2 2026: 2 added (0 new), 1 trimmed or exited.

  • Short sellersSTEADY

    Short interest −3.5% to 45.2K shares. 1.0 days to cover, ≈0.3% of shares.

  • TrendDOWNTREND

    47% below its 50-day average. New closing low $0.2400 on Oct 23.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
CITADEL ADVISORS LLCADD23,205$12.8K
Allworth Financial LPDOUBLED172$95.00
UBS Group AGNEAR_EXIT3$2.00

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

last action May 2026

Fresh Price Targets

Analyst price targets updated within the last 24 hours are for subscribers only.

Subscribe for Full Access
Recent actions
DateFirmActionRating
May 11, 2026Maxim Group
INITIATE
INITIATEBuy
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Oct 2, 2026
Press release
20/20 BioLabs to Participate in the Maxim Growth Summit 2026 in New York on October 14, 2026
20/20 BioLabs to Participate in the Maxim Growth Summit 2026 in New York on October 14, 2026
Sep 29, 2026
Press release
20/20 BioLabs to Host Investor Webinar on October 7, 2026 to Discuss FDA Advisory Committee Vote and New OneTest™ Franchise Model
20/20 BioLabs to Host Investor Webinar on October 7, 2026 to Discuss FDA Advisory Committee Vote and New OneTest™ Franchise Model
Aug 28, 2026
Press release
20/20 BioLabs Reschedules Investor Webinar to 2:00 p.m. Eastern Time on September 2, 2026 to Discuss OneTest™ Revenue and Expanding Commercial Opportunity
20/20 BioLabs Reschedules Investor Webinar to 2:00 p.m. Eastern Time on September 2, 2026 to Discuss OneTest™ Revenue and Expanding Commercial…
Aug 17, 2026
Earnings
20/20 BioLabs Reports Second Quarter 2026 Financial Results and Recent Operational Progress, as Cancer Test Revenue Reaches Record Quarterly Level
20/20 BioLabs Reports Second Quarter 2026 Financial Results and Recent Operational Progress, as Cancer Test Revenue Reaches Record Quarterly Level
Jul 27, 2026
Press release
20/20 BioLabs Participates in BIO Asia-Taiwan and Meets with Strategic Counterparties in Taipei, Tokyo, and Seoul to Advance East Asia Roll-Up Strategy
20/20 BioLabs Participates in BIO Asia-Taiwan and Meets with Strategic Counterparties in Taipei, Tokyo, and Seoul to Advance East Asia Roll-Up…

Insider ledger

Form 4
$0
open-market buys or sells · 12 mo
DateInsiderTypeValue
Apr 2, 2026
Bergman Alan B.
Chief Financial Officer
AWARD100,000 sh
Apr 2, 2026
Zhou Jiming
Chief Operating Officer
AWARD150,000 sh
Mar 3, 2026
Cohen Jonathan M
Chief Executive Officer
AWARD352,936 sh
Feb 19, 2026
Rollins John Woodson
Director
CONVERT6,135 sh
Feb 19, 2026
COHEN RICHARD M
Director
CONVERT7,700 sh
Feb 19, 2026
COHEN RICHARD M
Director
CONVERT7,700 sh
Feb 19, 2026
Compton John G.
Director
CONVERT7,669 sh
Feb 19, 2026
Ross Michael A.
Director
CONVERT31 sh

Earnings setup

Estimates

Revision history: 🔒 Fresh data — subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data — subscribers only
Next Q🔒 Fresh data — subscribers only
Current FY🔒 Fresh data — subscribers only
Next FY🔒 Fresh data — subscribers only

Short side

FINRA· Sep 30, 2026
45,167
shares short
-3.5%
vs prior settlement
1.0
days to cover
≈0.3%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 21, 2026 SEC
20/20 Biolabs, Inc. filed definitive additional proxy soliciting materials (DEFA14A) for a special meeting of…
DEFA14A — Impact 3/10
Oct 21, 2026 SEC
20/20 Biolabs, Inc. is holding a Special Meeting on December 9, 2026 to seek stockholder approval for a reverse stock…
DEF 14A — Impact 5/10
Oct 2, 2026 Other
20/20 BioLabs to Participate in the Maxim Growth Summit 2026 in New York on October 14, 2026
20/20 BioLabs to Participate in the Maxim Growth Summit 2026 in New York on October 14, 2026
Aug 17, 2026 SEC
20/20 BioLabs reported Q2 2026 revenue of $0.7M (+36.5% YoY), driven by a record quarter for its OneTest MCED cancer…
8-K — Impact 6/10
Jun 30, 2026 Inst.
CITADEL ADVISORS LLC — ADD
23,205 shares ($12.8K)
Jun 30, 2026 Inst.
Allworth Financial LP — DOUBLED
172 shares ($95.00)
Apr 2, 2026 Insider
Bergman Alan B. was granted 100,000 shares
Chief Financial Officer
Apr 2, 2026 Insider
Zhou Jiming was granted 150,000 shares
Chief Operating Officer

SecBot reports

12 filings · 2 press releases · 1 bullish · 4 bearish · 7 neutral
All AIDX filing & press-release reports (14)